CIK 0001776111
- Non-accelerated filer
- Smaller reporting company
- Emerging growth company
MBX Biosciences, Inc.
Sign in to watch- Ticker
- MBX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- Phone
- +1 317-989-3100
- Business address
- 11711 N. MERIDIAN STREET, SUITE 300, CARMEL, IN, 46032
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $288,361
- in 2 filings
Net −$288,361. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-05-06 | Hawryluk P. Kent President & CEO | Sale | −607 | $29.54 | $18K | 727,667 |
| 2026-03-13 | Hawryluk P. Kent President & CEO | Purchase | +18,500 | $28.41 | $526K | 486,777 |
| 2026-02-26 | Hawryluk P. Kent President & CEO | Exercise or conversion | +28,768 | $16.00 | $460K | 728,274 |
| 2026-02-26 | Hawryluk P. Kent President & CEO | Exercise or conversion · Stock option (right to buy) | −28,768 | 91,668 | ||
| 2026-02-02 | Hawryluk P. Kent President & CEO | Grant or award | +35,250 | 699,506 | ||
| 2026-02-02 | Hawryluk P. Kent President & CEO | Grant or award · Stock option (right to buy) | +164,500 | 164,500 | ||
| 2025-10-24 | Hawryluk P. Kent President & CEO | Exercise or conversion | +182,859 | $3.25 | $594K | 664,256 |
| 2025-10-24 | Hawryluk P. Kent President & CEO | Exercise or conversion · Stock option (right to buy) | −182,859 | 129,708 | ||
| 2025-10-20 | Hawryluk P. Kent President & CEO | Purchase | +20,000 | $13.64 | $273K | 468,277 |
| 2025-02-04 | Hawryluk P. Kent President & CEO | Purchase | +50,000 | $10.69 | $535K | 448,277 |
| 2025-02-03 | Hawryluk P. Kent President & CEO | Grant or award · Stock Option (Right to Buy) | +243,000 | 243,000 | ||
| 2024-09-16 | Hawryluk P. Kent President & CEO | Conversion | +283,846 | 481,397 | ||
| 2024-09-16 | Hawryluk P. Kent President & CEO | Conversion | +115,914 | 398,277 | ||
| 2024-09-16 | Hawryluk P. Kent President & CEO | Conversion · Series A Convertible Preferred Stock | −2,015,681 | 0 | ||
| 2024-09-16 | Hawryluk P. Kent President & CEO | Conversion · Series A Convertible Preferred Stock | −345,705 | 0 | ||
| 2024-09-16 | Hawryluk P. Kent President & CEO | Conversion · Series B Convertible Preferred Stock | −1,396,762 | 0 | ||
| 2024-09-16 | Hawryluk P. Kent President & CEO | Conversion · Series B Convertible Preferred Stock | −76,969 | 0 | ||
| 2024-09-16 | Hawryluk P. Kent President & CEO | Conversion · Series C Convertible Preferred Stock | −970,873 | 0 | ||
| 2024-09-12 | Hawryluk P. Kent President & CEO | Grant or award · Stock Option (Right to Buy) | +120,436 | 120,436 |
Page 1 of 1 · 19 trades